original ) (raw )Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Richard Silver
Journal of hematology & oncology, 2017
View PDFchevron_right
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
Heike Pahl
Annals of Hematology
View PDFchevron_right
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis
Nicholas Sarlis
Haematologica, 2015
View PDFchevron_right
The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases
sezgin etgül
International Journal of Hematology and Oncology, 2016
View PDFchevron_right
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
Alessandro Vannucchi
Journal of hematology & oncology, 2017
View PDFchevron_right
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Richard Silver
Haematologica, 2015
View PDFchevron_right
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Richard Silver
British Journal of Haematology, 2013
View PDFchevron_right
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly
Ohad Benjamini
Blood, 2012
View PDFchevron_right
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study
Catherine Bouard
Leukemia & Lymphoma, 2020
View PDFchevron_right
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients
Gianni Binotto
Leukemia Research, 2018
View PDFchevron_right
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Richard Silver
Journal of Clinical Oncology, 2013
View PDFchevron_right
Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis
kate burbury
Blood, 2020
View PDFchevron_right
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study
Pilar Giraldo
Hematological Oncology, 2021
View PDFchevron_right
Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
Nicholas Sarlis
Leukemia Research, 2013
View PDFchevron_right
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
Timothy Devos
Journal of Clinical Oncology
View PDFchevron_right
Real-life ruxolitinib experience in intermediate-risk myelofibrosis
I. Kaygusuz
Blood Research, 2021
View PDFchevron_right
Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
John Mascarenhas
Clinical lymphoma, myeloma & leukemia, 2014
View PDFchevron_right
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial
Anita Szőke
JAMA oncology, 2018
View PDFchevron_right
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Sanjay Akhani
Future Oncology
View PDFchevron_right
Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012
Mary McMullin
British Journal of Haematology, 2014
View PDFchevron_right
Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study
Evdoxia Hatjiharissi
Blood, 2016
View PDFchevron_right
A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence
Ros Wade
PharmacoEconomics, 2016
View PDFchevron_right
Myelofibrozis hastalarında Ruxolitinib kullanımı: tek merkez deneyimi ve JAK-2 allel yükü ile Ruxolitinib yanıtı arasındaki ilişki
Mesut Gocer
Pamukkale Medical Journal, 2020
View PDFchevron_right
Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I)
Richard Silver
Blood, 2011
View PDFchevron_right
Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients
Daniel El Fassi
Blood, 2020
View PDFchevron_right
Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib
Ramy Abdelrahman
Leukemia, 2014
View PDFchevron_right
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
Paola Guglielmelli
Blood, 2014
View PDFchevron_right
Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey
emin kaya
TURKISH JOURNAL OF MEDICAL SCIENCES, 2021
View PDFchevron_right
Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis
Francesco Mendicino
Future oncology (London, England), 2015
View PDFchevron_right
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
Nicola Polverelli
Oncotarget, 2017
View PDFchevron_right
Comparison Study between Real Life and Published Data Outcome among Myelofibrosis Patients Who are Using Ruxolitinib at King Abdulaziz Medical City-Central Region
Mohamed Albekery
2020
View PDFchevron_right
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study
Nicola Polverelli
Hematological oncology, 2017
View PDFchevron_right
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
Alfredo Molteni
Blood Advances, 2022
View PDFchevron_right
Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
Francesco Mendicino
Current Oncology
View PDFchevron_right